Email a Friend
To: (email address)
From: (email address)
Email Subject:
Note: (optional)
255 character limit
Based on the impressive results of the JUPITER trial, CRESTOR® (rosuvastatin calcium) has a primary prevention of cardiovascular disease (CVD) indication.
CRESTOR is indicated in patients without clinically evident coronary heart disease (CHD), to reduce the risk of myocardial infarction, stroke, and arterial revascularization in men ≥50 years and women ≥60 years with hsCRP ≥2 mg/L and at least one additional cardiovascular disease risk factor.1,2
In the JUPITER trial, CRESTOR 20 mg vs placebo demonstrated1,2
54% relative risk reduction in myocardial infarction (P<.001)
0.4% absolute risk reduction
48% relative risk reduction in stroke (P=.002)
0.3% absolute risk reduction
46% relative risk reduction in arterial revascularization (P<.001)
0.7% absolute risk reduction
Click on the "+" and "—" signs to expand and collapse the clinical information.
‡Subject to eligibility. Restrictions apply. Click here for eligibility information.
Risk reduction of myocardial infarction with CRESTOR vs placebo1,2
Adapted from the JUPITER Trial
Risk reduction of stroke with CRESTOR vs placebo1,2
Adapted from the JUPITER Trial
Risk reduction of arterial revascularization* with CRESTOR vs placebo1,2
Adapted from the JUPITER Trial
Next: Patient Savings Card
You may report side effects related to AstraZeneca products by clicking here.